Less than 10% of individuals who could benefit from obesity jabs such as Wegovy have access to them, states the World Health Organization as it issues its first recommendations on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for increased and just availability to these injectable treatments.
According to projections, more than two billion could be obese by 2030 without intervention.
"The new guidance acknowledges that excess weight is a chronic disease that can be addressed with thorough and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are key hurdles to broad availability to the injections that can aid individuals in losing considerable body mass, says the body.
Skinny Jab Shortage
Even in the present best projected scenario, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – less than 10% of eligible patients, according to the health organization.
The guideline calls on nations and manufacturers to increase availability, by measures including licensing agreements.
A patent on semaglutide – the core component of the drug Wegovy – is due to expire in several nations in 2026.
How Weight-Loss Injections Operate
The injections mimick a body's own hormone to slow digestion, suppress the appetite and increase satiety so individuals eat less.
Patients commonly start to lose weight in the initial weeks of beginning the regular doses.
Studies indicates patients may see weight return after a year of stopping the treatment, as their typical food cravings come back.
Being carrying excess weight increases your risk for developing diseases, such as diabetes, heart disease, brain attack, and some cancers.
Obesity impacts individuals in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
